All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

IV tPA remains the standard of care of acute ischemic stroke patients presenting within established time windows without contraindications, and hospitals should continue to concentrate on system ...

A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its older approval in acute ST-elevation myocardial infarction. Tenecteplase ...

Intravenous delivered tPA is approved by the FDA for the treatment of acute ischemic stroke. The drug can make a big difference, but only if it is given within a specified time frame (up to four and a ...